First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

author
created [InstanceEdit:9685099] Jassal, Bijay, 2020-04-22
dbId 9685083
displayName First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
journal Clin. Cancer Res.
pages 1536-1545
pubMedIdentifier 29217526
schemaClass LiteratureReference
title First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
url http://www.ncbi.nlm.nih.gov/pubmed/29217526
volume 24
year 2018
Cite Us!